Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. reduced its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 50.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 11,641 shares of the biotechnology company’s stock after selling 11,951 shares during the quarter. Principal Financial Group Inc.’s holdings in Aurinia Pharmaceuticals were worth $85,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of AUPH. FMR LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after acquiring an additional 3,919 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Aurinia Pharmaceuticals by 10.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the biotechnology company’s stock valued at $301,000 after purchasing an additional 4,808 shares in the last quarter. Handelsbanken Fonder AB increased its position in Aurinia Pharmaceuticals by 13.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 60,700 shares of the biotechnology company’s stock worth $445,000 after purchasing an additional 7,100 shares during the period. PFG Investments LLC raised its stake in shares of Aurinia Pharmaceuticals by 37.9% during the 2nd quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company’s stock worth $164,000 after buying an additional 7,900 shares in the last quarter. Finally, CWM LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 247.7% in the 3rd quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock valued at $84,000 after buying an additional 8,180 shares during the period. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Up 0.5 %

AUPH opened at $8.42 on Wednesday. Aurinia Pharmaceuticals Inc. has a one year low of $4.71 and a one year high of $10.67. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -56.13 and a beta of 1.24. The business’s fifty day moving average is $8.67 and its two-hundred day moving average is $7.16. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60.

Insider Buying and Selling

In other Aurinia Pharmaceuticals news, Director Jeffrey Allen Bailey sold 4,557 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $8.43, for a total transaction of $38,415.51. Following the sale, the director now owns 13,356 shares in the company, valued at approximately $112,591.08. This represents a 25.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

AUPH has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Monday, September 16th. StockNews.com downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, December 13th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.